Remove Clinic Remove Definition Remove Disease Remove PET Scan
article thumbnail

PET Scans Reveal ‘smoldering’ Inflammation in patients with Multiple sclerosis

Imaging Technology

The findings were published in Clinical Nuclear Medicine. Microglia are immune cells in the brain that are thought to have a role in MS disease progression but cannot be seen by a routine MRI. The team developed a technique called F18 PBR 06 PET imaging.

PET Scan 102
article thumbnail

Can PET help diagnose neurosarcoidosis?

AuntMinnie

FDG-PET imaging shows promise for use as a diagnostic criterion for neurosarcoidosis, with a recent case series illustrating the approach was effective when gold-standard approaches were not, according to a group of researchers in Berlin. “To In all three cases, gadolinium-enhanced MRI scans did not show abnormalities.

Diagnose 108
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Researchers offer hypothesis for long COVID brain fog

AuntMinnie

A group in France has offered an explanation for long COVID brain fog, with the concept based on a visual brain pattern they discovered on patient PET scans, according to a study published October 13 in Medical Hypotheses. “We A) PET scan of a healthy subject. (B) B) PET scan of a long COVID patient.

PET Scan 145
article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

article thumbnail

The rise of theranostics: Part 4 -- Women's theranostics on the horizon

AuntMinnie

Gayton oversees clinical operations at Precirix and serves as the company's chief development officer. With CAM-H2, we engineered the protein to bind to a different epitope on HER2 to other approved therapies, so the option of combining CAM-H2 with other therapies is definitely an opportunity."

Disease 105